Results from London Regional Clinical Genetics services over a 5-year period on germline TP53 testing in women diagnosed with breast cancer at <30 years
BackgroundThe most common cancer diagnosed in germline TP53 pathogenic variant (PV) carriers is premenopausal breast cancer. An increased rate of breast tumour HER2 positivity has been reported in this group. Screening for breast/other cancers is recommended in PV carriers.Objectives1. To assess the...
Saved in:
Published in | Journal of medical genetics Vol. 59; no. 6; pp. 554 - 558 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BMJ Publishing Group Ltd
01.06.2022
BMJ Publishing Group LTD |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!